Global Transthyretin Amyloidosis (ATTR) Market Size By Type (Hereditary ATTR (HATTR), Wild-Type (WT) ATTR), By Application (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2...

The Global Transthyretin Amyloidosis (ATTR) Market was valued at USD X billion in 2023 and is expected to surpass USD X billion by 2031, registering a CAGR of X.X% during the forecast period of 2023-2031. The increasing prevalence of hereditary and wild-type ATTR, advancements in therapeutic developments, and rising awareness about amyloidosis diagnosis are driving market growth. The ATTR market is witnessing innovation in treatment modalities, including gene-silencing therapies and transthyretin stabilizers, which are improving patient outcomes and expanding market opportunities.

Drivers

Rising Prevalence of ATTR

The increasing incidence of hereditary (hATTR) and wild-type ATTR (wtATTR) is a significant growth driver for the market. The disease, primarily affecting the heart and nervous system, has gained medical attention due to its progressive nature and underdiagnosis in earlier years.

Advancements in Therapeutic Approaches

Innovations in treatment approaches, such as RNA interference (RNAi) therapies, gene silencing techniques, and TTR stabilizers, have enhanced disease management, improving patient survival rates. The introduction of therapies like patisiran, inotersen, and tafamidis has revolutionized treatment for ATTR patients.

Growing Awareness and Early Diagnosis

Awareness initiatives by medical organizations and increased access to genetic testing and diagnostic imaging have improved early diagnosis rates, significantly boosting demand for ATTR-specific therapies.

Restraints

High Cost of Treatment

Advanced therapies for ATTR, such as TTR stabilizers and RNAi-based treatments, come with high treatment costs, making affordability a challenge, particularly in developing economies.

Limited Patient Access to Advanced Treatments

Despite the availability of novel ATTR treatments, limited reimbursement policies and regulatory hurdles in certain regions are impeding market penetration and widespread accessibility.

Opportunities

Pipeline Advancements and Novel Therapies

Ongoing clinical trials for next-generation gene-silencing therapies and TTR stabilizers are expected to drive significant market expansion. The development of orally available ATTR treatments presents a key opportunity for growth.

Emerging Markets Adoption

The expansion of ATTR treatment access in emerging economies, supported by government healthcare initiatives and improved medical infrastructure, presents lucrative opportunities for market players.

Market by Treatment Type Insights

Based on treatment type, TTR stabilizers accounted for the largest market share in 2023, driven by their effectiveness in slowing disease progression. However, RNA interference therapies are projected to grow at the highest CAGR due to their disease-modifying potential.

Market by End-Use Insights

Hospitals and specialized clinics emerged as the largest revenue contributors in 2023, owing to the increasing preference for hospital-based administration of RNAi therapies and growing healthcare infrastructure supporting ATTR treatments.

Market by Regional Insights

North America held the largest market share in 2023, driven by advanced healthcare infrastructure, rising ATTR diagnosis rates, and strong presence of key pharmaceutical companies. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period, fueled by improving diagnostic capabilities and increasing government healthcare investments.

Competitive Scenario

Key players operating in the Global Transthyretin Amyloidosis (ATTR) Market include:

Pfizer Inc.

Alnylam Pharmaceuticals

Ionis Pharmaceuticals

BridgeBio Pharma

Eidos Therapeutics

Alexion Pharmaceuticals

These companies are focusing on R&D investment, strategic collaborations, and geographical expansion to strengthen their market presence. Notable recent developments include:

2023: Alnylam Pharmaceuticals expanded its RNAi-based ATTR therapy to additional markets.

2024: Pfizer announced further clinical trials for tafamidis in additional ATTR subtypes.

2025: BridgeBio Pharma launched a novel small-molecule stabilizer targeting wild-type ATTR.

Scope of Work – Global Transthyretin Amyloidosis (ATTR) Market